Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced NSCLC With EGFR Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06109558
What this trial is testing

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

Who this might be right for
Non Small Cell Lung CancerRET Gene MutationMET Amplification+1 more
Hunan Province Tumor Hospital 120
Early research (Phase 1)Ended earlyNCT03054038
What this trial is testing

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Carcinoma
Vanderbilt-Ingram Cancer Center 22
Testing effectiveness (Phase 2)Study completedNCT01372384
What this trial is testing

Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 6
Testing effectiveness (Phase 2)UnknownNCT01955421
What this trial is testing

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc

Who this might be right for
Advanced Stage Non Small Cell Lung Cancer
Sun Yat-sen University 224
Testing effectiveness (Phase 2)Looking for participantsNCT07079475
What this trial is testing

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

Who this might be right for
Non-Small Cell Lung Cancer
Dizal Pharmaceuticals 220
Not applicableNot Yet RecruitingNCT07714304
What this trial is testing

JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC

Who this might be right for
NSCLC Harboring EGFR Mutations
Huan Zhou 20
Testing effectiveness (Phase 2)Study completedNCT02976116
What this trial is testing

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

Who this might be right for
NSCLC
Hutchison Medipharma Limited 50
Early research (Phase 1)Not Yet RecruitingNCT06015568
What this trial is testing

Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation

Who this might be right for
Non-Small Cell Lung Cancer、EGFR Sensitive Mutation
Betta Pharmaceuticals Co., Ltd. 172
Large-scale testing (Phase 3)UnknownNCT03856697
What this trial is testing

Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

Who this might be right for
Advanced Non-small Cell Lung Cancer
Hangzhou ACEA Pharmaceutical Research Co., Ltd. 406
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07709585
What this trial is testing

Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients

Who this might be right for
Advanced Non-small Cell Lung Cancer (NSCLC)EGFR Exon 19 Deletion MutationEGFR Exon 21 Mutation+1 more
Guangzhou University of Traditional Chinese Medicine 124
Large-scale testing (Phase 3)UnknownNCT04028778
What this trial is testing

Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC

Who this might be right for
Lung Cancer, Nonsmall Cell
Sun Yat-sen University 310
Large-scale testing (Phase 3)UnknownNCT04500717
What this trial is testing

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation

Who this might be right for
Non Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 460
Testing effectiveness (Phase 2)Ended earlyNCT05215951
What this trial is testing

Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC

Who this might be right for
Lung Cancer
AstraZeneca 4
Testing effectiveness (Phase 2)Active Not RecruitingNCT05466149
What this trial is testing

Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion

Who this might be right for
NSCLC
Allist Pharmaceuticals, Inc. 100
Testing effectiveness (Phase 2)Ended earlyNCT02095782
What this trial is testing

Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation

Who this might be right for
Non-small-cell Lung Cancer
Guangdong Association of Clinical Trials 10
Testing effectiveness (Phase 2)Looking for participantsNCT06706076
What this trial is testing

BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
BlossomHill Therapeutics 675
Testing effectiveness (Phase 2)Looking for participantsNCT06222489
What this trial is testing

Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT

Who this might be right for
Non-Small Cell Lung CarcinomaAdvanced Non-Small Cell Squamous Lung CancerEGFR Gene Mutation
The Netherlands Cancer Institute 16
Testing effectiveness (Phase 2)Study completedNCT04184921
What this trial is testing

Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients

Who this might be right for
Lung Cancer Non-small Cell Stage IV
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 216
Testing effectiveness (Phase 2)UnknownNCT03460275
What this trial is testing

Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 100
Large-scale testing (Phase 3)Looking for participantsNCT07155187
What this trial is testing

Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
AbbVie 490
Next Page